Prevention of age-associated dementia

Brain Research Bulletin

Volumn 80, Issue 4-5, 2009, Pages 315-325

  Mohajeri, M Hasan ^a   Leuba, Genevieve ^b  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b Unit of Biochemistry and Clinical Psychopharmacology   (Switzerland)

Author keywords

Alzheimer; Diet; Immune system; Nutrition; Risk factor; Side effect; Therapy

Indexed keywords

ADJUVANT; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN ANTIBODY; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; BETA SECRETASE INHIBITOR; CLIOQUINOL; CYCLOOXYGENASE 2 INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; PLACEBO; TARENFLURBIL; VITAMIN;

AGING; ALZHEIMER DISEASE; BIOACCUMULATION; CLINICAL TRIAL; DEMENTIA; ENCEPHALITIS; FEEDING BEHAVIOR; HUMAN; IMMUNE SYSTEM; IMMUNIZATION; LIFE EXPECTANCY; MENINGOENCEPHALITIS; NEUROFIBRILLARY TANGLE; NONHUMAN; ONSET AGE; PASSIVE IMMUNIZATION; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROTEIN FOLDING; REVIEW; VASCULAR DISEASE;

AGING; ANIMALS; DEMENTIA; HUMANS; IMMUNOTHERAPY; MICE; RISK REDUCTION BEHAVIOR;

EID: 70349435938     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2009.06.014     Document Type: Review

References (169)

1. Abad-Rodriguez J., Ledesma M.D., Craessaerts K., Perga S., Medina M., Delacourte A., Dingwall C., De Strooper B., and Dotti C.G. Neuronal membrane cholesterol loss enhances amyloid peptide generation. J. Cell. Biol. 167 (2004) 953-960
2. Agca C., Fritz J.J., Walker L.C., Levey A.I., Chan A.W., Lah J.J., and Agca Y. Development of transgenic rats producing human beta-amyloid precursor protein as a model for Alzheimer's disease: transgene and endogenous APP genes are regulated tissue-specifically. BMC Neurosci. 9 (2008) 28
3. Arnold S.E., Hyman B.T., Flory J., Damasio A.R., and Van Hoesen G.W. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cereb. Cortex 1 (1991) 103-116
4. Bacskai B.J., Kajdasz S.T., Christie R.H., Carter C., Games D., Seubert P., Schenk D., and Hyman B.T. Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat. Med. 7 (2001) 369-372
5. Bacskai B.J., Kajdasz S.T., McLellan M.E., Games D., Seubert P., Schenk D., and Hyman B.T. Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J. Neurosci. 22 (2002) 7873-7878
6. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Lieberburg I., Motter R., Nguyen M., Soriano F., Vasquez N., Weiss K., Welch B., Seubert P., Schenk D., and Yednock T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6 (2000) 916-919
7. Bentahir M., Nyabi O., Verhamme J., Tolia A., Horre K., Wiltfang J., Esselmann H., and De Strooper B. Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. J. Neurochem. 96 (2006) 732-742
8. Benton D., Kallus K.W., and Schmitt J.A. How should we measure nutrition-induced improvements in memory?. Eur. J. Nutr. 44 (2005) 485-498
9. Berchtold N.C., Chinn G., Chou M., Kesslak J.P., and Cotman C.W. Exercise primes a molecular memory for brain-derived neurotrophic factor protein induction in the rat hippocampus. Neuroscience 133 (2005) 853-861
10. Berchtold N.C., Kesslak J.P., and Cotman C.W. Hippocampal brain-derived neurotrophic factor gene regulation by exercise and the medial septum. J. Neurosci. Res. 68 (2002) 511-521
11. Boncristiano S., Calhoun M.E., Kelly P.H., Pfeifer M., Bondolfi L., Stalder M., Phinney A.L., Abramowski D., Sturchler-Pierrat C., Enz A., Sommer B., Staufenbiel M., and Jucker M. Cholinergic changes in the APP23 transgenic mouse model of cerebral amyloidosis. J. Neurosci. 22 (2002) 3234-3243
12. Brazil M.I., Chung H., and Maxfield F.R. Effects of incorporation of immunoglobulin G and complement component C1q on uptake and degradation of Alzheimer's disease amyloid fibrils by microglia. J. Biol. Chem. 275 (2000) 16941-16947
13. Bu G. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat. Rev. Neurosci. 10 (2009) 333-344
14. Buee L., Bussiere T., Buee-Scherrer V., Delacourte A., and Hof P.R. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Rev. 33 (2000) 95-130
15. Calhoun M.E., Burgermeister P., Phinney A.L., Stalder M., Tolnay M., Wiederhold K.H., Abramowski D., Sturchler-Pierrat C., Sommer B., Staufenbiel M., and Jucker M. Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 14088-14093
16. Calon F., Lim G.P., Morihara T., Yang F., Ubeda O., Salem Jr. N., Frautschy S.A., and Cole G.M. Dietary n-3 polyunsaturated fatty acid depletion activates caspases and decreases NMDA receptors in the brain of a transgenic mouse model of Alzheimer's disease. Eur. J. Neurosci. 22 (2005) 617-626
17. Calon F., Lim G.P., Yang F., Morihara T., Teter B., Ubeda O., Rostaing P., Triller A., Salem Jr. N., Ashe K.H., Frautschy S.A., and Cole G.M. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 43 (2004) 633-645
18. Chacon M.A., Barria M.I., Soto C., and Inestrosa N.C. Beta-sheet breaker peptide prevents Abeta-induced spatial memory impairments with partial reduction of amyloid deposits. Mol. Psychiatry 9 (2004) 953-961
19. Check E. Nerve inflammation halts trial for Alzheimer's drug. Nature 415 (2002) 462
20. Chen G., Chen K.S., Knox J., Inglis J., Bernard A., Martin S.J., Justice A., McConlogue L., Games D., Freedman S.B., and Morris R.G. A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature 408 (2000) 975-979
21. Cheng I.H., Palop J.J., Esposito L.A., Bien-Ly N., Yan F., and Mucke L. Aggressive amyloidosis in mice expressing human amyloid peptides with the Arctic mutation. Nat. Med. 10 (2004) 1190-1192
22. Cherny R.A., Atwood C.S., Xilinas M.E., Gray D.N., Jones W.D., McLean C.A., Barnham K.J., Volitakis I., Fraser F.W., Kim Y., Huang X., Goldstein L.E., Moir R.D., Lim J.T., Beyreuther K., Zheng H., Tanzi R.E., Masters C.L., and Bush A.I. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30 (2001) 665-676
23. Chishti M.A., Yang D.S., Janus C., Phinney A.L., Horne P., Pearson J., Strome R., Zuker N., Loukides J., French J., Turner S., Lozza G., Grilli M., Kunicki S., Morissette C., Paquette J., Gervais F., Bergeron C., Fraser P.E., Carlson G.A., George-Hyslop P.S., and Westaway D. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J. Biol. Chem. 276 (2001) 21562-21570
24. Citron M., Westaway D., Xia W., Carlson G., Diehl T., Levesque G., Johnson-Wood K., Lee M., Seubert P., Davis A., Kholodenko D., Motter R., Sherrington R., Perry B., Yao H., Strome R., Lieberburg I., Rommens J., Kim S., Schenk D., Fraser P., St George Hyslop P., and Selkoe D.J. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat. Med. 3 (1997) 67-72
25. Colcombe S.J., Kramer A.F., Erickson K.I., Scalf P., McAuley E., Cohen N.J., Webb A., Jerome G.J., Marquez D.X., and Elavsky S. Cardiovascular fitness, cortical plasticity, and aging. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 3316-3321
26. Crameri A., Biondi E., Kuehnle K., Lutjohann D., Thelen K.M., Perga S., Dotti C.G., Nitsch R.M., Ledesma M.D., and Mohajeri M.H. The role of seladin-1/DHCR24 in cholesterol biosynthesis, APP processing and Abeta generation in vivo. EMBO J. 25 (2006) 432-443
27. Crowther R.A., and Wischik C.M. Image reconstruction of the Alzheimer paired helical filament. EMBO J. 4 (1985) 3661-3665
28. Delacourte A., David J.P., Sergeant N., Buee L., Wattez A., Vermersch P., Ghozali F., Fallet-Bianco C., Pasquier F., Lebert F., Petit H., and Di Menza C. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease. Neurology 52 (1999) 1158-1165
29. Delacourte A., Sergeant N., Champain D., Wattez A., Maurage C.A., Lebert F., Pasquier F., and David J.P. Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer's disease. Neurology 59 (2002) 398-407
30. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M., and Holtzman D.M. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 8850-8855
31. Deng Y., Tarassishin L., Kallhoff V., Peethumnongsin E., Wu L., Li Y.M., and Zheng H. Deletion of presenilin 1 hydrophilic loop sequence leads to impaired gamma-secretase activity and exacerbated amyloid pathology. J. Neurosci. 26 (2006) 3845-3854
32. Deshpande A., Kawai H., Metherate R., Glabe C.G., and Busciglio J. A role for synaptic zinc in activity-dependent Abeta oligomer formation and accumulation at excitatory synapses. J. Neurosci. 29 (2009) 4004-4015
33. Dewachter I., Van Dorpe J., Smeijers L., Gilis M., Kuiperi C., Laenen I., Caluwaerts N., Moechars D., Checler F., Vanderstichele H., and Van Leuven F. Aging increased amyloid peptide and caused amyloid plaques in brain of old APP/V717I transgenic mice by a different mechanism than mutant presenilin1. J. Neurosci. 20 (2000) 6452-6458
34. Dewachter I., van Dorpe J., Spittaels K., Tesseur I., Van Den Haute C., Moechars D., and Van Leuven F. Modeling Alzheimer's disease in transgenic mice: effect of age and of presenilin1 on amyloid biochemistry and pathology in APP/London mice. Exp. Gerontol. 35 (2000) 831-841
35. Dodart J.C., Bales K.R., Gannon K.S., Greene S.J., DeMattos R.B., Mathis C., DeLong C.A., Wu S., Wu X., Holtzman D.M., and Paul S.M. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat. Neurosci. 5 (2002) 452-457
36. Dominguez-del-Toro E., Rodriguez-Moreno A., Porras-Garcia E., Sanchez-Campusano R., Blanchard V., Laville M., Bohme G.A., Benavides J., and Delgado-Garcia J.M. An in vitro and in vivo study of early deficits in associative learning in transgenic mice that over-express a mutant form of human APP associated with Alzheimer's disease. Eur. J. Neurosci. 20 (2004) 1945-1952
37. Duff K., Eckman C., Zehr C., Yu X., Prada C.M., Perez-tur J., Hutton M., Buee L., Harigaya Y., Yager D., Morgan D., Gordon M.N., Holcomb L., Refolo L., Zenk B., Hardy J., and Younkin S. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature 383 (1996) 710-713
38. Eckman E.A., Watson M., Marlow L., Sambamurti K., and Eckman C.B. Alzheimer's disease beta-amyloid peptide is increased in mice deficient in endothelin-converting enzyme. J. Biol. Chem. 278 (2003) 2081-2084
39. Ellis R.J., Olichney J.M., Thal L.J., Mirra S.S., Morris J.C., Beekly D., and Heyman A. Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: the CERAD experience. Part XV. Neurology 46 (1996) 1592-1596
40. Farris W., Mansourian S., Chang Y., Lindsley L., Eckman E.A., Frosch M.P., Eckman C.B., Tanzi R.E., Selkoe D.J., and Guenette S. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 4162-4167
41. Ferrer I., Boada Rovira M., Sanchez Guerra M.L., Rey M.J., and Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol. 14 (2004) 11-20
42. Fratiglioni L., Paillard-Borg S., and Winblad B. An active and socially integrated lifestyle in late life might protect against dementia. Lancet Neurol. 3 (2004) 343-353
43. Frenkel D., Katz O., and Solomon B. Immunization against Alzheimer's beta-amyloid plaques via EFRH phage administration. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 11455-11459
44. Furlan R., Brambilla E., Sanvito F., Roccatagliata L., Olivieri S., Bergami A., Pluchino S., Uccelli A., Comi G., and Martino G. Vaccination with amyloid-beta peptide induces autoimmune encephalomyelitis in C57/BL6 mice. Brain 126 (2003) 285-291
45. Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., Carr T., Clemens J., Donaldson T., Gillespie F., et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373 (1995) 523-527
46. Games D., Buttini M., Kobayashi D., Schenk D., and Seubert P. Mice as models: transgenic approaches and Alzheimer's disease. J. Alzheimers Dis. 9 (2006) 133-149
47. Gaugler M.N., Tracy J., Kuhnle K., Crameri A., Nitsch R.M., and Mohajeri M.H. Modulation of Alzheimer's pathology by cerebro-ventricular grafting of hybridoma cells expressing antibodies against Abeta in vivo. FEBS Lett. 579 (2005) 753-756
48. Geula C., Wu C.K., Saroff D., Lorenzo A., Yuan M., and Yankner B.A. Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity. Nat. Med. 4 (1998) 827-831
49. Glabe C.G. Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. Neurobiol. Aging 27 (2006) 570-575
50. Glenner G.G., and Wong C.W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120 (1984) 885-890
51. Goedert M., Wischik C.M., Crowther R.A., Walker J.E., and Klug A. Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 4051-4055
52. Golde T.E. The therapeutic importance of understanding mechanisms of neuronal cell death in neurodegenerative disease. Mol. Neurodegener. 4 (2009) 8
53. Gura T. Hope in Alzheimer's fight emerges from unexpected places. Nat. Med. 14 (2008) 894
54. Hebert L.E., Scherr P.A., Bienias J.L., Bennett D.A., and Evans D.A. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch. Neurol. 60 (2003) 1119-1122
55. Herzig M.C., Winkler D.T., Burgermeister P., Pfeifer M., Kohler E., Schmidt S.D., Danner S., Abramowski D., Sturchler-Pierrat C., Burki K., van Duinen S.G., Maat-Schieman M.L., Staufenbiel M., Mathews P.M., and Jucker M. Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nat. Neurosci. 7 (2004) 954-960
56. Hock C., Konietzko U., Papassotiropoulos A., Wollmer A., Streffer J., von Rotz R.C., Davey G., Moritz E., and Nitsch R.M. Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. Nat. Med. 8 (2002) 1270-1275
57. Hock C., Konietzko U., Streffer J.R., Tracy J., Signorell A., Muller-Tillmanns B., Lemke U., Henke K., Moritz E., Garcia E., Wollmer M.A., Umbricht D., de Quervain D.J., Hofmann M., Maddalena A., Papassotiropoulos A., and Nitsch R.M. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38 (2003) 547-554
58. Holmes C., Boche D., Wilkinson D., Yadegarfar G., Hopkins V., Bayer A., Jones R.W., Bullock R., Love S., Neal J.W., Zotova E., and Nicoll J.A. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372 (2008) 216-223
59. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., and Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274 (1996) 99-102
60. Hsiao K.K., Borchelt D.R., Olson K., Johannsdottir R., Kitt C., Yunis W., Xu S., Eckman C., Younkin S., Price D., et al. Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron 15 (1995) 1203-1218
61. Ibach B., Haen E., Marienhagen J., and Hajak G. Clioquinol treatment in familiar early onset of Alzheimer's disease: a case report. Pharmacopsychiatry 38 (2005) 178-179
62. Iwata N., Takaki Y., Fukami S., Tsubuki S., and Saido T.C. Region-specific reduction of A beta-degrading endopeptidase, neprilysin, in mouse hippocampus upon aging. J. Neurosci. Res. 70 (2002) 493-500
63. Iwata N., Tsubuki S., Takaki Y., Shirotani K., Lu B., Gerard N.P., Gerard C., Hama E., Lee H.J., and Saido T.C. Metabolic regulation of brain Abeta by neprilysin. Science 292 (2001) 1550-1552
64. Iwata N., Tsubuki S., Takaki Y., Watanabe K., Sekiguchi M., Hosoki E., Kawashima-Morishima M., Lee H.J., Hama E., Sekine-Aizawa Y., and Saido T.C. Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat. Med. 6 (2000) 143-150
65. Janus C., Chishti M.A., and Westaway D. Transgenic mouse models of Alzheimer's disease. Biochim. Biophys. Acta 1502 (2000) 63-75
66. Janus C., D'Amelio S., Amitay O., Chishti M.A., Strome R., Fraser P., Carlson G.A., Roder J.C., St George-Hyslop P., and Westaway D. Spatial learning in transgenic mice expressing human presenilin 1 (PS1) transgenes. Neurobiol. Aging 21 (2000) 541-549
67. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., Chishti M.A., Horne P., Heslin D., French J., Mount H.T., Nixon R.A., Mercken M., Bergeron C., Fraser P.E., St George-Hyslop P., and Westaway D. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408 (2000) 979-982
68. Karp A., Paillard-Borg S., Wang H.X., Silverstein M., Winblad B., and Fratiglioni L. Mental, physical and social components in leisure activities equally contribute to decrease dementia risk. Dement. Geriatr. Cogn. Disord. 21 (2006) 65-73
69. Kellner A., Matschke J., Bernreuther C., Moch H., Ferrer I., and Glatzel M. Autoantibodies against beta-amyloid are common in Alzheimer's disease and help control plaque burden. Ann. Neurol. 65 (2009) 24-31
70. Kidd P. Alzheimer's disease, amnestic mild cognitive impairment, and age-associated memory impairment: current understanding and progress toward integrative prevention. Altern. Med. Rev. 13 (2008) 85-115
71. Kivipelto M., and Solomon A. Alzheimer's disease-the ways of prevention. J. Nutr. Health Aging 12 (2008) 89S-94S
72. Kivipelto M., and Solomon A. Cholesterol as a risk factor for Alzheimer's disease-epidemiological evidence. Acta Neurol. Scand. Suppl. 185 (2006) 50-57
73. Koller M.F., Mohajeri M.H., et al. Immunization of mice with an Aβ-Hsp70 vaccine elicits anti-Aβ antibodies and increased cerebral Aβ-levels. Neurodeg. Dis. 1 (2004) 20-28
74. Kotilinek L.A., Bacskai B., Westerman M., Kawarabayashi T., Younkin L., Hyman B.T., Younkin S., and Ashe K.H. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J. Neurosci. 22 (2002) 6331-6335
75. Kramer A.F., Hahn S., Cohen N.J., Banich M.T., McAuley E., Harrison C.R., Chason J., Vakil E., Bardell L., Boileau R.A., and Colcombe A. Ageing, fitness and neurocognitive function. Nature 400 (1999) 418-419
76. Kumar-Singh S., Theuns J., Van Broeck B., Pirici D., Vennekens K., Corsmit E., Cruts M., Dermaut B., Wang R., and Van Broeckhoven C. Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40. Hum. Mutat. 27 (2006) 686-695
77. Lahiri D.K., Farlow M.R., Sambamurti K., Greig N.H., Giacobini E., and Schneider L.S. A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease. Curr. Drug Targets 4 (2003) 97-112
78. Laitinen M.H., Ngandu T., Rovio S., Helkala E.L., Uusitalo U., Viitanen M., Nissinen A., Tuomilehto J., Soininen H., and Kivipelto M. Fat intake at midlife and risk of dementia and Alzheimer's disease: a population-based study. Dement. Geriatr. Cogn. Disord. 22 (2006) 99-107
79. Laurin D., Verreault R., Lindsay J., MacPherson K., and Rockwood K. Physical activity and risk of cognitive impairment and dementia in elderly persons. Arch. Neurol. 58 (2001) 498-504
80. Lee J.Y., Cole T.B., Palmiter R.D., Suh S.W., and Koh J.Y. Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 7705-7710
81. Lee M., Bard F., Johnson-Wood K., Lee C., Hu K., Griffith S.G., Black R.S., Schenk D., and Seubert P. Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies. Ann. Neurol. 58 (2005) 430-435
82. Lee V.M., Goedert M., and Trojanowski J.Q. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24 (2001) 1121-1159
83. Leissring M.A., Farris W., Chang A.Y., Walsh D.M., Wu X., Sun X., Frosch M.P., and Selkoe D.J. Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 40 (2003) 1087-1093
84. Levy-Lahad E., Wasco W., Poorkaj P., Romano D.M., Oshima J., Pettingell W.H., Yu C.E., Jondro P.D., Schmidt S.D., Wang K., et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 269 (1995) 973-977
85. Lewis J., McGowan E., Rockwood J., Melrose H., Nacharaju P., Van Slegtenhorst M., Gwinn-Hardy K., Paul Murphy M., Baker M., Yu X., Duff K., Hardy J., Corral A., Lin W.L., Yen S.H., Dickson D.W., Davies P., and Hutton M. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet. 25 (2000) 402-405
86. Lichtenberg B., Mandelkow E.M., Hagestedt T., and Mandelkow E. Structure and elasticity of microtubule-associated protein tau. Nature 334 (1988) 359-362
87. Lichtlen P., and Mohajeri M.H. Antibody-based approaches in Alzheimer's research: safety, pharmacokinetics, metabolism, and analytical tools. J. Neurochem. 104 (2008) 859-874
88. Liu J.P. New functions of cholesterol binding proteins. Mol. Cell. Endocrinol. 303 (2009) 1-6
89. Madani R., Poirier R., Wolfer D.P., Welzl H., Groscurth P., Lipp H.P., Lu B., El Mouedden M., Mercken M., Nitsch R.M., and Mohajeri M.H. Lack of neprilysin suffices to generate murine amyloid-like deposits in the brain and behavioral deficit in vivo. J. Neurosci. Res. 84 (2006) 1871-1878
90. Maruyama M., Higuchi M., Takaki Y., Matsuba Y., Tanji H., Nemoto M., Tomita N., Matsui T., Iwata N., Mizukami H., Muramatsu S., Ozawa K., Saido T.C., Arai H., and Sasaki H. Cerebrospinal fluid neprilysin is reduced in prodromal Alzheimer's disease. Ann. Neurol. 57 (2005) 832-842
91. Masters C.L., Multhaup G., Simms G., Pottgiesser J., Martins R.N., and Beyreuther K. Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J. 4 (1985) 2757-2763
92. Masters C.L., Simms G., Weinman N.A., Multhaup G., McDonald B.L., and Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. U.S.A. 82 (1985) 4245-4249
93. Mohajeri M.H. The underestimated potential of the immune system in prevention of Alzheimer's disease pathology. Bioessays 29 (2007) 927-932
94. Mohajeri M.H., Gaugler M.N., Martinez J., Tracy J., Li H., Crameri A., Kuehnle K., Wollmer M.A., and Nitsch R.M. Assessment of the bioactivity of antibodies against beta-amyloid peptide in vitro and in vivo. Neurodegener. Dis. 1 (2004) 160-167
95. Mohajeri M.H., and Wolfer D.P. Neprilysin deficiency-dependent impairment of cognitive functions in a mouse model of amyloidosis. Neurochem. Res. 34 (2009) 717-726
96. Mohajeri M.H., Wollmer M.A., and Nitsch R.M. Abeta 42-induced increase in neprilysin is associated with prevention of amyloid plaque formation in vivo. J. Biol. Chem. 277 (2002) 35460-35465
97. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., Duff K., Jantzen P., DiCarlo G., Wilcock D., Connor K., Hatcher J., Hope C., Gordon M., and Arendash G.W. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408 (2000) 982-985
98. Mucke L., Masliah E., Yu G.Q., Mallory M., Rockenstein E.M., Tatsuno G., Hu K., Kholodenko D., Johnson-Wood K., and McConlogue L. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20 (2000) 4050-4058
99. Nicoll J.A., Wilkinson D., Holmes C., Steart P., Markham H., and Weller R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 9 (2003) 448-452
100. Obeid R., and Herrmann W. Mechanisms of homocysteine neurotoxicity in neurodegenerative diseases with special reference to dementia. FEBS Lett. 580 (2006) 2994-3005
101. Oddo S., Caccamo A., Kitazawa M., Tseng B.P., and LaFerla F.M. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol. Aging 24 (2003) 1063-1070
102. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., and LaFerla F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39 (2003) 409-421
103. Oksman M., Iivonen H., Hogyes E., Amtul Z., Penke B., Leenders I., Broersen L., Lutjohann D., Hartmann T., and Tanila H. Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on beta-amyloid accumulation in APP/PS1 transgenic mice. Neurobiol. Dis. 23 (2006) 563-572
104. O'Nuallain B., Hrncic R., Wall J.S., Weiss D.T., and Solomon A. Diagnostic and therapeutic potential of amyloid-reactive IgG antibodies contained in human sera. J. Immunol. 176 (2006) 7071-7078
105. Orgogozo J.M., Gilman S., Dartigues J.F., Laurent B., Puel M., Kirby L.C., Jouanny P., Dubois B., Eisner L., Flitman S., Michel B.F., Boada M., Frank A., and Hock C. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61 (2003) 46-54
106. Papassotiropoulos A., Streffer J.R., Tsolaki M., Schmid S., Thal D., Nicosia F., Iakovidou V., Maddalena A., Lutjohann D., Ghebremedhin E., Hegi T., Pasch T., Traxler M., Bruhl A., Benussi L., Binetti G., Braak H., Nitsch R.M., and Hock C. Increased brain beta-amyloid load, phosphorylated tau, and risk of Alzheimer disease associated with an intronic CYP46 polymorphism. Arch. Neurol. 60 (2003) 29-35
107. Paresce D.M., Ghosh R.N., and Maxfield F.R. Microglial cells internalize aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor. Neuron 17 (1996) 553-565
108. Permanne B., Adessi C., Saborio G.P., Fraga S., Frossard M.J., Van Dorpe J., Dewachter I., Banks W.A., Van Leuven F., and Soto C. Reduction of amyloid load and cerebral damage in a transgenic mouse model of Alzheimer's disease by treatment with a beta-sheet breaker peptide. FASEB J. 16 (2002) 860-862
109. Pfeifer M., Boncristiano S., Bondolfi L., Stalder A., Deller T., Staufenbiel M., Mathews P.M., and Jucker M. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 298 (2002) 1379
110. Poirier R., Wolfer D.P., Welzl H., Tracy J., Galsworthy M.J., Nitsch R.M., and Mohajeri M.H. Neuronal neprilysin overexpression is associated with attenuation of Abeta-related spatial memory deficit. Neurobiol. Dis. 24 (2006) 475-483
111. Puglielli L., Tanzi R.E., and Kovacs D.M. Alzheimer's disease: the cholesterol connection. Nat. Neurosci. 6 (2003) 345-351
112. Relkin N.R., Mujalli D., Shennoy S.A., Adamiak B., Kayed W.M.E.R., et al. IVIg contains antibodies against oligomers and fibrils of beta amyloid. Alzheimer Dement. 3 (2007) S196
113. Relkin N.R., Szabo P., Adamiak B., Burgut T., Monthe C., Lent R.W., Younkin S., Younkin L., Schiff R., and Weksler M.E. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol. Aging (2008)
114. Revesz T., Holton J.L., Lashley T., Plant G., Rostagno A., Ghiso J., and Frangione B. Sporadic and familial cerebral amyloid angiopathies. Brain Pathol. 12 (2002) 343-357
115. Ritchie C.W., Cappai R., and Masters C. Clioquinol treatment in familiar early onset of Alzheimer's disease. Pharmacopsychiatry 39 (2006) 80
116. Ibach B., et al. Pharmacopsychiatry 38 (2005) 178-179
117. Roberds S.L., Anderson J., Basi G., Bienkowski M.J., Branstetter D.G., Chen K.S., Freedman S.B., Frigon N.L., Games D., Hu K., Johnson-Wood K., Kappenman K.E., Kawabe T.T., Kola I., Kuehn R., Lee M., Liu W., Motter R., Nichols N.F., Power M., Robertson D.W., Schenk D., Schoor M., Shopp G.M., Shuck M.E., Sinha S., Svensson K.A., Tatsuno G., Tintrup H., Wijsman J., Wright S., and McConlogue L. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum. Mol. Genet. 10 (2001) 1317-1324
118. Robinson S.R., Bishop G.M., Lee H.G., and Munch G. Lessons from the AN 1792 Alzheimer vaccine: lest we forget. Neurobiol. Aging 25 (2004) 609-615
119. Rocchi A., Pellegrini S., Siciliano G., and Murri L. Causative and susceptibility genes for Alzheimer's disease: a review. Brain Res. Bull. 61 (2003) 1-24
120. Rockwood K. Epidemiological and clinical trials evidence about a preventive role for statins in Alzheimer's disease. Acta Neurol. Scand. Suppl. 185 (2006) 71-77
121. Rogaeva E., Meng Y., Lee J.H., Gu Y., Kawarai T., Zou F., Katayama T., Baldwin C.T., Cheng R., Hasegawa H., Chen F., Shibata N., Lunetta K.L., Pardossi-Piquard R., Bohm C., Wakutani Y., Cupples L.A., Cuenco K.T., Green R.C., Pinessi L., Rainero I., Sorbi S., Bruni A., Duara R., Friedland R.P., Inzelberg R., Hampe W., Bujo H., Song Y.Q., Andersen O.M., Willnow T.E., Graff-Radford N., Petersen R.C., Dickson D., Der S.D., Fraser P.E., Schmitt-Ulms G., Younkin S., Mayeux R., Farrer L.A., and St George-Hyslop P. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat. Genet. 39 (2007) 168-177
122. Rosendorff C., Beeri M.S., and Silverman J.M. Cardiovascular risk factors for Alzheimer's disease. Am. J. Geriatr. Cardiol. 16 (2007) 143-149
123. Rovelet-Lecrux A., Hannequin D., Raux G., Le Meur N., Laquerriere A., Vital A., Dumanchin C., Feuillette S., Brice A., Vercelletto M., Dubas F., Frebourg T., and Campion D. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat. Genet. 38 (2006) 24-26
124. Rovio S., Kareholt I., Helkala E.L., Viitanen M., Winblad B., Tuomilehto J., Soininen H., Nissinen A., and Kivipelto M. Leisure-time physical activity at midlife and the risk of dementia and Alzheimer's disease. Lancet Neurol. 4 (2005) 705-711
125. Rovio S., Kareholt I., Viitanen M., Winblad B., Tuomilehto J., Soininen H., Nissinen A., and Kivipelto M. Work-related physical activity and the risk of dementia and Alzheimer's disease. Int. J. Geriatr. Psychiatry 22 (2007) 874-882
126. Saido T.C. Alzheimer's disease as proteolytic disorders: anabolism and catabolism of beta-amyloid. Neurobiol. Aging 19 (1998) S69-75
127. Saido T.C., and Nakahara H. In: Saido E.T.C. (Ed). Metabolism and Alzheimer's Disease (2003), Landes Bioscience, Georgetown, TX. http://www.eurekah.com/ Chap. 6 (see also http://www.eurekah.com)
128. Saura C.A., Choi S.Y., Beglopoulos V., Malkani S., Zhang D., Shankaranarayana Rao B.S., Chattarji S., Kelleher III R.J., Kandel E.R., Duff K., Kirkwood A., and Shen J. Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron 42 (2004) 23-36
129. Scarmeas N., Stern Y., Mayeux R., and Luchsinger J.A. Mediterranean diet, Alzheimer disease, and vascular mediation. Arch. Neurol. 63 (2006) 1709-1717
130. Scarmeas N., Stern Y., Tang M.X., Mayeux R., and Luchsinger J.A. Mediterranean diet and risk for Alzheimer's disease. Ann. Neurol. 59 (2006) 912-921
131. Schenk D. Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat. Rev. Neurosci. 3 (2002) 824-828
132. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., and Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400 (1999) 173-177
133. Schroeter S., Khan K., Barbour R., Doan M., Chen M., Guido T., Gill D., Basi G., Schenk D., Seubert P., and Games D. Immunotherapy reduces vascular amyloid-beta in PDAPP mice. J. Neurosci. 28 (2008) 6787-6793
134. Schweers O., Schonbrunn-Hanebeck E., Marx A., and Mandelkow E. Structural studies of tau protein and Alzheimer paired helical filaments show no evidence for beta-structure. J. Biol. Chem. 269 (1994) 24290-24297
135. Selkoe D.J. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav. Brain Res. 192 (2008) 106-113
136. Selkoe D.J. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 399 (1999) A23-A31
137. Senior K. Dosing in phase II trial of Alzheimer's vaccine suspended. Lancet Neurol. 1 (2002) 3
138. Shen H., Tong L., Balazs R., and Cotman C.W. Physical activity elicits sustained activation of the cyclic AMP response element-binding protein and mitogen-activated protein kinase in the rat hippocampus. Neuroscience 107 (2001) 219-229
139. Shen J., Bronson R.T., Chen D.F., Xia W., Selkoe D.J., and Tonegawa S. Skeletal and CNS defects in presenilin-1-deficient mice. Cell 89 (1997) 629-639
140. Sherrington R., Rogaev E.I., Liang Y., Rogaeva E.A., Levesque G., Ikeda M., Chi H., Lin C., Li G., Holman K., et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375 (1995) 754-760
141. Shibata M., Yamada S., Kumar S.R., Calero M., Bading J., Frangione B., Holtzman D.M., Miller C.A., Strickland D.K., Ghiso J., and Zlokovic B.V. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest. 106 (2000) 1489-1499
142. Snowdon D. Aging with Grace: What the Nun Study Teaches Us About Leading Longer, Healthier, and More Meaningful Lives (2002), Bantam Books, New York, NY
143. Soto C., Sigurdsson E.M., Morelli L., Kumar R.A., Castano E.M., and Frangione B. Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat. Med. 4 (1998) 822-826
144. Sparks D.L., Martins R., and Martin T. Cholesterol and cognition: rationale for the AD cholesterol-lowering treatment trial and sex-related differences in beta-amyloid accumulation in the brains of spontaneously hypercholesterolemic Watanabe rabbits. Ann. N. Y. Acad. Sci. 977 (2002) 356-366
145. Spooner E.T., Desai R.V., Mori C., Leverone J.F., and Lemere C.A. The generation and characterization of potentially therapeutic Abeta antibodies in mice: differences according to strain and immunization protocol. Vaccine 21 (2002) 290-297
146. Stalder M., Phinney A., Probst A., Sommer B., Staufenbiel M., and Jucker M. Association of microglia with amyloid plaques in brains of APP23 transgenic mice. Am. J. Pathol. 154 (1999) 1673-1684
147. Stefani M., and Liguri G. Cholesterol in Alzheimer's disease: unresolved questions. Curr. Alzheimer Res. 6 (2009) 15-29
148. Sturchler-Pierrat C., Abramowski D., Duke M., Wiederhold K.H., Mistl C., Rothacher S., Ledermann B., Burki K., Frey P., Paganetti P.A., Waridel C., Calhoun M.E., Jucker M., Probst A., Staufenbiel M., and Sommer B. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 13287-13292
149. Szabo P., Relkin N., and Weksler M.E. Natural human antibodies to amyloid beta peptide. Autoimmun. Rev. 7 (2008) 415-420
150. Tong L., Shen H., Perreau V.M., Balazs R., and Cotman C.W. Effects of exercise on gene-expression profile in the rat hippocampus. Neurobiol. Dis. 8 (2001) 1046-1056
151. Van Broeck B., Van Broeckhoven C., and Kumar-Singh S. Current insights into molecular mechanisms of Alzheimer disease and their implications for therapeutic approaches. Neurodegener. Dis. 4 (2007) 349-365
152. Van Broeckhoven C., Backhovens H., Cruts M., De Winter G., Bruyland M., Cras P., and Martin J.J. Mapping of a gene predisposing to early-onset Alzheimer's disease to chromosome 14q24.3. Nat. Genet. 2 (1992) 335-339
153. Van Dorpe J., Smeijers L., Dewachter I., Nuyens D., Spittaels K., Van Den Haute C., Mercken M., Moechars D., Laenen I., Kuiperi C., Bruynseels K., Tesseur I., Loos R., Vanderstichele H., Checler F., Sciot R., and Van Leuven F. Prominent cerebral amyloid angiopathy in transgenic mice overexpressing the London mutant of human APP in neurons. Am. J. Pathol. 157 (2000) 1283-1298
154. Vaya J., and Schipper H.M. Oxysterols, cholesterol homeostasis, and Alzheimer disease. J. Neurochem. 102 (2007) 1727-1737
155. Vehmas A.K., Borchelt D.R., Price D.L., McCarthy D., Wills-Karp M., Peper M.J., Rudow G., Luyinbazi J., Siew L.T., and Troncoso J.C. beta-Amyloid peptide vaccination results in marked changes in serum and brain Abeta levels in APPswe/PS1DeltaE9 mice, as detected by SELDI-TOF-based ProteinChip technology. DNA Cell Biol. 20 (2001) 713-721
156. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., and Selkoe D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416 (2002) 535-539
157. Wang R., Wang B., He W., and Zheng H. Wild-type presenilin 1 protects against Alzheimer disease mutation-induced amyloid pathology. J. Biol. Chem. 281 (2006) 15330-15336
158. Weksler M.E. The immunotherapy of Alzheimer's disease. Immun. Ageing 1 (2004) 1-7
159. Weksler M.E., Relkin N., Turkenich R., LaRusse S., Zhou L., and Szabo P. Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp. Gerontol. 37 (2002) 943-948
160. Wilcock G.K., Black S.E., Hendrix S.B., Zavitz K.H., Swabb E.A., and Laughlin M.A. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Lancet Neurol. 7 (2008) 483-493
161. Winkler D.T., Bondolfi L., Herzig M.C., Jann L., Calhoun M.E., Wiederhold K.H., Tolnay M., Staufenbiel M., and Jucker M. Spontaneous hemorrhagic stroke in a mouse model of cerebral amyloid angiopathy. J. Neurosci. 21 (2001) 1619-1627
162. Wischik C.M., Crowther R.A., Stewart M., and Roth M. Subunit structure of paired helical filaments in Alzheimer's disease. J. Cell. Biol. 100 (1985) 1905-1912
163. Wisniewski T., and Konietzko U. Amyloid-beta immunisation for Alzheimer's disease. Lancet Neurol. 7 (2008) 805-811
164. Wolozin B. Cyp46 (24S-cholesterol hydroxylase): a genetic risk factor for Alzheimer disease. Arch. Neurol. 60 (2003) 16-18
165. Wong G.T., Manfra D., Poulet F.M., Zhang Q., Josien H., Bara T., Engstrom L., Pinzon-Ortiz M., Fine J.S., Lee H.J., Zhang L., Higgins G.A., and Parker E.M. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J. Biol. Chem. 279 (2004) 12876-12882
166. Yan H., Dobbie Z., Gruber S.B., Markowitz S., Romans K., Giardiello F.M., Kinzler K.W., and Vogelstein B. Small changes in expression affect predisposition to tumorigenesis. Nat. Genet. 30 (2002) 25-26
167. Yan H., Yuan W., Velculescu V.E., Vogelstein B., and Kinzler K.W. Allelic variation in human gene expression. Science 297 (2002) 1143
168. Zugel U., and Kaufmann S.H. Immune response against heat shock proteins in infectious diseases. Immunobiology 201 (1999) 22-35
169. Zelcer N., Khanlou N., Clare R., Jiang Q., Reed-Geaghan E.G., Landreth G.E., Vinters H.V., and Tontonoz P. Attenuation of neuroinflammation and Alzheimer's disease pathology by liver × receptors. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 10601-10606